Patients with ApoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291→Ser mutation in the human LPL gene

Hanfang Zhang, Paul W.A. Reymer, Ming Sun Liu, Ian J. Forsythe, Bjorn E. Groenemeyer, Jiri Frohlich, John D. Brunzell, John J.P. Kastelein, Michael R. Hayden, Yuanhong Ma

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Approximately 1% to 2% of persons in the general population are homozygous for a lipoprotein receptor-binding defective form of apoE (apoE2/2). However, only a small percentage (2% to 5%) of all apoE2/2 homozygotes develop type III hyperlipoproteinemia. Interaction with other genetic and environmental factors are required for the expression of this lipid abnormality. We sought to investigate tile possible role of LPL gene mutations in the development of hyperlipoproteinemia in apoE2/2 homozygotes and in apoE2 heterozygotes. As a first step, we performed DNA sequence analysis of all 10 LPL coding exons in 2 patients with the apoE2/2 genotype who had type III hyperlipoproteinemia and identified a single missense mutation (Asn 291→Ser) in exon 6 of the LPL gene. The mutation was then found in 5 of 18 patients with type III hyperlipoproteinemia who had the apoE2/2 genotype (allele frequency 13.9%; P ≤ 7.4 x 10-5) and h of 22 hyperlipidemic E2 heterozygous patients with the apoE3/2 and E4/2 genotype (allele frequency 13.6%; P = 2.2 x 10-5). In contrast, this mutation was found in only 3 of 230 normolipidemic controls (allele frequency=0.7%). In vitro mutagenesis studies revealed that the Asn 291→Ser mutant LPL had approximately 60% of LPL catalytic activity and approximately 70% of specific activity compared with wild-type LPL. The heparin-binding affinity of the mutant LPL was not impaired. Our data suggest that the Asn 291→Ser substitution is likely to he a significant predisposing factor contributing to the expression of different forms of hyperlipidemia when associated with other genetic factors such as the presence of apoE2.

Original languageEnglish (US)
Pages (from-to)1695-1703
Number of pages9
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume15
Issue number10
DOIs
StatePublished - Jan 1 1995

Fingerprint

Apolipoprotein E2
Apolipoprotein E3
Hyperlipidemias
Hyperlipoproteinemia Type III
Mutation
Genes
Gene Frequency
Genotype
Homozygote
Exons
Lipoprotein Receptors
Hyperlipoproteinemias
Apolipoproteins E
Missense Mutation
Heterozygote
DNA Sequence Analysis
Mutagenesis
Causality
Heparin
Lipids

Keywords

  • apoE
  • gene- gene interaction
  • hyperlipoproteinemia
  • lipoprotein lipase
  • missense mutations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Patients with ApoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291→Ser mutation in the human LPL gene. / Zhang, Hanfang; Reymer, Paul W.A.; Liu, Ming Sun; Forsythe, Ian J.; Groenemeyer, Bjorn E.; Frohlich, Jiri; Brunzell, John D.; Kastelein, John J.P.; Hayden, Michael R.; Ma, Yuanhong.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 15, No. 10, 01.01.1995, p. 1695-1703.

Research output: Contribution to journalArticle

Zhang, H, Reymer, PWA, Liu, MS, Forsythe, IJ, Groenemeyer, BE, Frohlich, J, Brunzell, JD, Kastelein, JJP, Hayden, MR & Ma, Y 1995, 'Patients with ApoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291→Ser mutation in the human LPL gene', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, no. 10, pp. 1695-1703. https://doi.org/10.1161/01.ATV.15.10.1695
Zhang, Hanfang ; Reymer, Paul W.A. ; Liu, Ming Sun ; Forsythe, Ian J. ; Groenemeyer, Bjorn E. ; Frohlich, Jiri ; Brunzell, John D. ; Kastelein, John J.P. ; Hayden, Michael R. ; Ma, Yuanhong. / Patients with ApoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291→Ser mutation in the human LPL gene. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 1995 ; Vol. 15, No. 10. pp. 1695-1703.
@article{c8f74da8393e4d50a57efddbf00152c7,
title = "Patients with ApoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291→Ser mutation in the human LPL gene",
abstract = "Approximately 1{\%} to 2{\%} of persons in the general population are homozygous for a lipoprotein receptor-binding defective form of apoE (apoE2/2). However, only a small percentage (2{\%} to 5{\%}) of all apoE2/2 homozygotes develop type III hyperlipoproteinemia. Interaction with other genetic and environmental factors are required for the expression of this lipid abnormality. We sought to investigate tile possible role of LPL gene mutations in the development of hyperlipoproteinemia in apoE2/2 homozygotes and in apoE2 heterozygotes. As a first step, we performed DNA sequence analysis of all 10 LPL coding exons in 2 patients with the apoE2/2 genotype who had type III hyperlipoproteinemia and identified a single missense mutation (Asn 291→Ser) in exon 6 of the LPL gene. The mutation was then found in 5 of 18 patients with type III hyperlipoproteinemia who had the apoE2/2 genotype (allele frequency 13.9{\%}; P ≤ 7.4 x 10-5) and h of 22 hyperlipidemic E2 heterozygous patients with the apoE3/2 and E4/2 genotype (allele frequency 13.6{\%}; P = 2.2 x 10-5). In contrast, this mutation was found in only 3 of 230 normolipidemic controls (allele frequency=0.7{\%}). In vitro mutagenesis studies revealed that the Asn 291→Ser mutant LPL had approximately 60{\%} of LPL catalytic activity and approximately 70{\%} of specific activity compared with wild-type LPL. The heparin-binding affinity of the mutant LPL was not impaired. Our data suggest that the Asn 291→Ser substitution is likely to he a significant predisposing factor contributing to the expression of different forms of hyperlipidemia when associated with other genetic factors such as the presence of apoE2.",
keywords = "apoE, gene- gene interaction, hyperlipoproteinemia, lipoprotein lipase, missense mutations",
author = "Hanfang Zhang and Reymer, {Paul W.A.} and Liu, {Ming Sun} and Forsythe, {Ian J.} and Groenemeyer, {Bjorn E.} and Jiri Frohlich and Brunzell, {John D.} and Kastelein, {John J.P.} and Hayden, {Michael R.} and Yuanhong Ma",
year = "1995",
month = "1",
day = "1",
doi = "10.1161/01.ATV.15.10.1695",
language = "English (US)",
volume = "15",
pages = "1695--1703",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Patients with ApoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291→Ser mutation in the human LPL gene

AU - Zhang, Hanfang

AU - Reymer, Paul W.A.

AU - Liu, Ming Sun

AU - Forsythe, Ian J.

AU - Groenemeyer, Bjorn E.

AU - Frohlich, Jiri

AU - Brunzell, John D.

AU - Kastelein, John J.P.

AU - Hayden, Michael R.

AU - Ma, Yuanhong

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Approximately 1% to 2% of persons in the general population are homozygous for a lipoprotein receptor-binding defective form of apoE (apoE2/2). However, only a small percentage (2% to 5%) of all apoE2/2 homozygotes develop type III hyperlipoproteinemia. Interaction with other genetic and environmental factors are required for the expression of this lipid abnormality. We sought to investigate tile possible role of LPL gene mutations in the development of hyperlipoproteinemia in apoE2/2 homozygotes and in apoE2 heterozygotes. As a first step, we performed DNA sequence analysis of all 10 LPL coding exons in 2 patients with the apoE2/2 genotype who had type III hyperlipoproteinemia and identified a single missense mutation (Asn 291→Ser) in exon 6 of the LPL gene. The mutation was then found in 5 of 18 patients with type III hyperlipoproteinemia who had the apoE2/2 genotype (allele frequency 13.9%; P ≤ 7.4 x 10-5) and h of 22 hyperlipidemic E2 heterozygous patients with the apoE3/2 and E4/2 genotype (allele frequency 13.6%; P = 2.2 x 10-5). In contrast, this mutation was found in only 3 of 230 normolipidemic controls (allele frequency=0.7%). In vitro mutagenesis studies revealed that the Asn 291→Ser mutant LPL had approximately 60% of LPL catalytic activity and approximately 70% of specific activity compared with wild-type LPL. The heparin-binding affinity of the mutant LPL was not impaired. Our data suggest that the Asn 291→Ser substitution is likely to he a significant predisposing factor contributing to the expression of different forms of hyperlipidemia when associated with other genetic factors such as the presence of apoE2.

AB - Approximately 1% to 2% of persons in the general population are homozygous for a lipoprotein receptor-binding defective form of apoE (apoE2/2). However, only a small percentage (2% to 5%) of all apoE2/2 homozygotes develop type III hyperlipoproteinemia. Interaction with other genetic and environmental factors are required for the expression of this lipid abnormality. We sought to investigate tile possible role of LPL gene mutations in the development of hyperlipoproteinemia in apoE2/2 homozygotes and in apoE2 heterozygotes. As a first step, we performed DNA sequence analysis of all 10 LPL coding exons in 2 patients with the apoE2/2 genotype who had type III hyperlipoproteinemia and identified a single missense mutation (Asn 291→Ser) in exon 6 of the LPL gene. The mutation was then found in 5 of 18 patients with type III hyperlipoproteinemia who had the apoE2/2 genotype (allele frequency 13.9%; P ≤ 7.4 x 10-5) and h of 22 hyperlipidemic E2 heterozygous patients with the apoE3/2 and E4/2 genotype (allele frequency 13.6%; P = 2.2 x 10-5). In contrast, this mutation was found in only 3 of 230 normolipidemic controls (allele frequency=0.7%). In vitro mutagenesis studies revealed that the Asn 291→Ser mutant LPL had approximately 60% of LPL catalytic activity and approximately 70% of specific activity compared with wild-type LPL. The heparin-binding affinity of the mutant LPL was not impaired. Our data suggest that the Asn 291→Ser substitution is likely to he a significant predisposing factor contributing to the expression of different forms of hyperlipidemia when associated with other genetic factors such as the presence of apoE2.

KW - apoE

KW - gene- gene interaction

KW - hyperlipoproteinemia

KW - lipoprotein lipase

KW - missense mutations

UR - http://www.scopus.com/inward/record.url?scp=0029130943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029130943&partnerID=8YFLogxK

U2 - 10.1161/01.ATV.15.10.1695

DO - 10.1161/01.ATV.15.10.1695

M3 - Article

VL - 15

SP - 1695

EP - 1703

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 10

ER -